National League campaign raises £150,000 for Prostate Cancer UK

Kevin Webber at The Shay on Saturday
Kevin Webber at The Shay on Saturday

The #MANarama campaign - a partnership between Vanarama and Prostate Cancer UK - has raised £150,000 for the cancer charity.

Vanarama’s cheque for £150,000 was presented to Prostate Cancer UK at the FC Halifax Town v Chesterfield game at The Shay on Saturday, which was Non-League Day.

The presentation party included ultra-marathon hero Kevin Webber, who had just completed seven walking marathons in seven days.

Diagnosed with incurable prostate cancer in November 2014 and told he could have as little as two years left to live, the Kevin has raised thousands for the charity in a series of epic endurance events and in the build-up to Non-League Day he walked more than 180 miles from Blyth Spartans to FC Halifax Town.

In total, he visited 10 National League clubs, hand-delivering unique captains’ armbands to be worn by all teams on Non-League Day.

National League Chief Executive Michael Tattersall, who walked alongside Kevin in the final day of his challenge, said: “We’re delighted at the response of our temporary – and historic - rebranding to the MANarama National League over the past six weeks, and it’s wonderful to see so much money and awareness raised to aid the fight against prostate cancer.

“We are proud to have Prostate Cancer UK as our first ever charity partner and look forward to working with them more going forward.

“This deadly disease has no boundaries, so it’s been incredibly inspiring to see Kevin Webber raise so much awareness within many of our membership. He’s a remarkable man doing remarkable things and we will continue to stand alongside him and everyone affected by prostate cancer.”

More than 11,000 men die from prostate cancer in the UK each year – that’s one man every 45 minutes. It’s the third biggest cancer killer.

It’s the most common cancer in men, with over 400,000 living with and after the disease in the UK.

Prostate cancer is set to become the most commonly diagnosed cancer of all in the UK by 2030.